ClostraBio
- Company typePrivate
- Founded2017
- HeadquartersChicago, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
ClostraBio firmographics
Firmographics- Name
- ClostraBio
- Legal name
- ClostraBio, Inc.
- Website
- https://clostrabio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
ClostraBio industry classification
Industry- Product category
- Probiotic & Gut Health Therapeutics
- NAICS
- Food Manufacturing (311)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Microbiome-Derived Metabolite Therapeutics (postbiotics) (HLAAAFAB)
- akta.pro secondary industries
- Probiotics & Digestive Health Supplements (CRADAGAF), Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases) (AFAJAJAE)
Keywords
Where ClostraBio is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ClostraBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations
Revenue model
- Probiotic Dietary Supplement Sales (CLB101): Direct sales of CLB101 probiotic supplement through e-commerce and partner distribution channels (Designs for Health, Maypro) targeting gut health consumers and healthcare practitioners.
- Therapeutic Development (CLB-004): Development of CLB-004 therapeutic asset for IBD (ulcerative colitis) through clinical trials. Intended to be developed as a pharmaceutical product with potential licensing or commercialization.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
ClostraBio product offering
Product offeringCore offering
ClostraBio develops and sells CLB101, a next-generation butyrate-producing probiotic dietary supplement featuring the Anaerostipes caccae CLB101 strain with self-affirmed GRAS status, and is developing CLB-004, a proprietary oral targeted metabolite delivery platform using block copolymer micelles for controlled release of butyrate in the lower gut to treat inflammatory bowel disease (IBD) and food allergies.
Product overview
ClostraBio offers two distinct products: (1) CLB101™, a next-generation probiotic dietary supplement launched commercially in Fall 2025, which delivers butyrate-producing bacteria directly to the gut; and (2) CLB-004, a proprietary therapeutic drug delivery platform using polymeric micelle technology for targeted, extended release of butyrate to treat IBD and food allergy. The company focuses on restoration of intestinal barrier-protective function and innate immunity through metabolite delivery solutions.
Differentiator
Problem solved
Functional benefit
Brands
- CLB101: Next-generation probiotic featuring Anaerostipes caccae CLB101 strain, designed to support gut barrier function, immunity, and balanced gut microbiome by producing butyrate directly in the gut.
- CLB-004
- Anaerostipes Probiotic
Products and services
- CLB101 Probiotic A next-generation probiotic dietary supplement featuring Anaerostipes caccae CLB101, a butyrate-producing strain isolated from healthy humans. CLB101 supports gut barrier function, immunity, and a balanced gut microbiome by producing butyrate directly in the lower intestine. It has been granted self-affirmed GRAS status and was launched commercially in Fall 2025.
- CLB-004 A proprietary, oral, targeted metabolite delivery platform using block copolymers that self-assemble into micelles to protect and stabilize butyrate, releasing it enzymatically in the ileum, cecum, and colon. CLB-004 is being developed to treat inflammatory bowel disease (IBD) and food allergy by modulating barrier function and immune response without suppressing immunity. IND-enabling toxicology studies are underway with plans for Phase 1a/b clinical studies in mild-moderate ulcerative colitis.
Quantifiable outcome
- Clinical study with 48 subjects evaluating CLB101 safety, tolerability, and gut health benefits including intestinal barrier integrity
- +1 more outcomes
Companies that use ClostraBio
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
ClostraBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ClostraBio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- MayprocorePartnership to launch CLB101 probiotic in North America. Maypro provides distribution capabilities for the gut health product that produces butyrate directly to support gut barrier integrity.
- Designs for HealthcoreStrategic collaboration for commercial launch of probiotic product featuring CLB101 strain. Designs for Health, a healthcare practitioner-focused supplement brand, distributes the Anaerostipes Probiotic product targeting gut dysfunction. ClostraBio also conducting clinical study to evaluate safety and gut health benefits.
- Scott Ravech (Board Appointment)coreIndustry veteran Scott Ravech appointed to Board of Directors. Ravech has extensive experience in probiotics industry, having led Deerland Probiotics & Enzymes through acquisition by ADM.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
ClostraBio competitors and assessment
Company assessmentDirect peers
- Pendulum Therapeutics: Direct peer developing next-generation probiotics targeting gut health and metabolic conditions, including glucose control. Comparable to ClostraBio in its emphasis on mechanistic, strain-specific probiotic innovation and direct-to-consumer plus practitioner distribution.
- Seed Health: Direct peer producing microbially-based consumer probiotics and synbiotics for gut and vaginal health. Comparable to ClostraBio's CLB101 in targeting science-forward consumers with proprietary probiotic strains via DTC and partner channels.
- Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for IBD and other indications. Most directly comparable to ClostraBio's CLB-004 therapeutic program in mechanism (microbiome-derived therapy) and indication overlap (ulcerative colitis).
- Seres Therapeutics: Microbiome therapeutics company that developed SER-109 (Vowst) for recurrent C. difficile and is advancing programs in IBD. Closely comparable to ClostraBio's CLB-004 in targeting gut-mediated disease with microbiome-derived approaches.
- BIOHM Health: Direct-to-consumer probiotics and microbiome testing company founded by Dr. Mahmoud Ghannoum targeting gut fungal and bacterial balance. Comparable to ClostraBio in consumer gut-health positioning and probiotic product focus.
- Evelo Biosciences: Clinical-stage company developing oral microbiome-based therapies for inflammatory diseases. Comparable to ClostraBio's CLB-004 in therapeutic modality (single-strain oral microbiome therapy) and inflammatory disease focus.
Broad incumbents
- Kerry Group (Ganeden): Large ingredients company that acquired Ganeden (a top-tier probiotic ingredient brand) and supplies probiotic strains to supplement and food manufacturers. Comparable as a broader incumbent in probiotic ingredients competing for the same channel partners and finished-product brand contracts.
- ADM (Deerland Probiotics & Enzymes): Global nutrition company that acquired Deerland Probiotics & Enzymes (led by Scott Ravech, now on ClostraBio's board). Comparable as a broad incumbent in probiotic ingredients, supplements, and enzymes competing in the same practitioner and CPG channels.
- BioGaia: Established Swedish probiotics company selling clinically documented Lactobacillus and Bifidobacterium strains across consumer and pediatric channels. Comparable as a broad incumbent with proprietary probiotic strains and global distribution.
Others
- Anokion (Hubbell-founded): Immune-tolerance therapeutics company co-founded by Prof. Jeffrey Hubbell (ClostraBio co-founder), targeting celiac disease and multiple sclerosis using red blood cell-engaging polymers. Thematically comparable as a Hubbell spinout leveraging immunoengineering in adjacent autoimmune indications.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ClostraBio social profiles
Digital presenceClostraBio compliance and trust
Trust signalCompliance1 record
ClostraBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
ClostraBio leadership team
Management profileNumber of profiles
Profiles13 records
ClostraBio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ClostraBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ClostraBio
What does ClostraBio do?
ClostraBio develops and sells CLB101, a next-generation butyrate-producing probiotic dietary supplement featuring the Anaerostipes caccae CLB101 strain with self-affirmed GRAS status, and is developing CLB-004, a proprietary oral targeted metabolite delivery platform using block copolymer micelles for controlled release of butyrate in the lower gut to treat inflammatory bowel disease (IBD) and food allergies.
Is ClostraBio a public or private company?
ClostraBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was ClostraBio founded?
ClostraBio was founded in 2017. It employs 1 to 10 people.
Where is ClostraBio based?
ClostraBio is headquartered in Chicago, United States, in the North America region.
How does ClostraBio make money?
Two revenue lines are on record. Probiotic Dietary Supplement Sales (CLB101) is the primary driver. The others are therapeutic Development (CLB-004).
Who are ClostraBio's main competitors?
Direct peers on record are Pendulum Therapeutics, Seed Health, Vedanta Biosciences, Seres Therapeutics, BIOHM Health and Evelo Biosciences. Broad incumbents are Kerry Group (Ganeden), ADM (Deerland Probiotics & Enzymes) and BioGaia. Anokion (Hubbell-founded) is listed as an others.
Does ClostraBio have an API?
No public API is recorded for ClostraBio.
What industry is ClostraBio in?
ClostraBio's product category is Probiotic & Gut Health Therapeutics. Its primary akta.pro industry code is HLAAAFAB, Microbiome-Derived Metabolite Therapeutics (postbiotics), with a secondary code of CRADAGAF, Probiotics & Digestive Health Supplements. Its NAICS code is 311 and its SIC code is 2836.